The invention relates to a new pharmaceutical composition, a method oftreatment of infection and also a process to prepare the composition. Theinfectious complications are important causes of morbidity and mortality.Hospital acquired pneumonia (HAP) remains the most severe nosocomial infectionin intensive care units. Beta-lactams alone are always considered inadequatewhen P. aeruginosa and / or methicillin-resistant S. aureus are implicated aspathogens or copathognes. The present invention provides the desired empiricaltherapy for control of all bacterial infections. The invention providesantibiotic combination products for delivering at least two differentantibiotics, through parenteral dosage form comprising protein-synthesis-inhibiting antibiotic which is amikacin or its sulphate salt and non-protein-synthesis-inhibiting antibiotic which is cefepime or its hydrochloride salt.The invention provides a total solution, against multiresistant P. aeruginosa,or Acinetobacter spp. and / or methicillin - resistant S. aureus, and areuseful for intramuscular or intravenous administration as antibiotics forhospitalized patients with acute or serious infections. The pharmaceuticalcompositions described here normally have the least nephrotoxicity and havebetter efficacy and safety of cefepime plus amikacin combination.
